產品櫥窗
-
Mifepristone, >98%
|
產品型號：101-84371-65-3 商品規格： |
 |
A kind of potent synthetic steroidal antiprogesterone. Synonym: 11β-(4-Dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-38486, RU-486
C29H35NO2
Mifepristone is an antagonist of glucocorticoid, progesterone, and androgen receptors. It is selective for these receptors over the mineralocorticoid receptor (MR), estrogen receptor α (ERα), and ERβ.
It also inhibits synthetic androgen R1881-stimulated reporter transcription in a concentration-dependent manner.2 Mifepristone (10 µM) inhibits growth of 4-OHT-resistant MCF-7 breast cancer cells in vitro. It also inhibits tumor growth in an SKOV3 ovarian cancer nude mouse xenograft model when administered at doses of 0.5 or 1 mg per day.
von Gerldern, T.W., Tu, N., Kym, P.R., et al. Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes. J. Med. Chem. 47(17), 4213-4230 (2004).
Song, L.-N., Coghlan, M.J., and Gelmann, E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18(1), 70-85 (2004).
Attardi, B.J., Burgenson, J., Hild, S.A., et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88(3), 277-288 (2004).
Gaddy, V.T., Barrett, J.T., Delk, J.N., et al. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clinical Cancer Research 10, 5215-5225 (2004).
Goyeneche, A.A., Carón, R.W., and Telleria, C.M. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin. Cancer Res. 13(11), 3370-3379 (2007).
M.W.: 429.59
Mifepristone is an antagonist of glucocorticoid, progesterone, and androgen receptors. It is selective for these receptors over the mineralocorticoid receptor (MR), estrogen receptor α (ERα), and ERβ.
It also inhibits synthetic androgen R1881-stimulated reporter transcription in a concentration-dependent manner.2 Mifepristone (10 µM) inhibits growth of 4-OHT-resistant MCF-7 breast cancer cells in vitro. It also inhibits tumor growth in an SKOV3 ovarian cancer nude mouse xenograft model when administered at doses of 0.5 or 1 mg per day.
von Gerldern, T.W., Tu, N., Kym, P.R., et al. Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes. J. Med. Chem. 47(17), 4213-4230 (2004).
Song, L.-N., Coghlan, M.J., and Gelmann, E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18(1), 70-85 (2004).
Attardi, B.J., Burgenson, J., Hild, S.A., et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88(3), 277-288 (2004).
Gaddy, V.T., Barrett, J.T., Delk, J.N., et al. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clinical Cancer Research 10, 5215-5225 (2004).
Goyeneche, A.A., Carón, R.W., and Telleria, C.M. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin. Cancer Res. 13(11), 3370-3379 (2007).
Store at -20℃
Shipping at Room Temp within Taiwan; may vary elsewhere
Shipping at Room Temp within Taiwan; may vary elsewhere